Intracellular Checkpoint in Orthogonal Cytokine Pathway

The "intracellular checkpoint in orthogonal cytokine pathway" refers to engineered molecular systems that allow precise, cell-intrinsic control of immune cell activation and function, particularly within adoptive T cell therapies. These systems are based on the use of orthogonal cytokine-receptor pairs, most notably involving interleukin-2 (IL-2) and its receptor IL-2Rβ, that have been modified so that only engineered T cells expressing the matching orthogonal receptor respond to the synthetic cytokine, while endogenous cells do not. Upon binding orthoIL-2, orthoIL-2Rβ initiates intracellular signaling cascades similar to native IL-2/IL‑2R interaction—primarily activating JAK/STAT pathways which drive proliferation, survival, and effector functions in T cells. Fusion with different intracellular domains can further tune downstream signaling strength and quality.

Other names

Orthogonal cytokine-receptor pairOrtho-hIL‐₂/Ortho-hIL‐₂Rβ system

Selective activation of genetically modified lymphocytes via orthogonal cytokine-receptor interaction, triggering downstream signaling cascades (JAK/STAT) and modulating immune cell function (proliferation, survival, cytotoxicity).